| HENRY FORD HEALTH SYSTEM Patent applications |
| Patent application number | Title | Published |
|---|
| 20120076759 | TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS). | 03-29-2012 |
| 20120059779 | Personalized Health Risk Assessment For Critical Care - A method for assessing whether a patient is at risk of developing a clinical condition includes receiving training data representing a set of patient-related variables for each of a plurality of patients; generating model data based on the received training data; receiving target data representing the set of patient-related variables for a target patient; determining a risk level for the target patient of developing the clinical condition; and indicating the risk level of the target patient, where the set of patient-related variables consists of a first set of variables when the clinical condition is a mortality condition and a second set of variables when the clinical condition is a morbidity condition. | 03-08-2012 |
| 20120041393 | Apparatus and Method for Capsule Formation in Tissue - Capsules, emplacement apparatus, and associated methods for establishing a capsule within tissue are described herein. The emplacement apparatus may be catheter-based or implemented in a handheld unit. The emplacement apparatus serves to introduced an encapsulating membrane in a collapsed condition into the tissue, and then to expand the encapsulating membrane within the tissue into a capsule by injection of fill material into the encapsulating membrane. Other than being capable of injection through the emplacement apparatus, the fill material may be selected and formulated to achieve such mechanical and biological properties within the encapsulating membrane after injection as are desired to achieve the therapeutic effect sought for the patient. Mechanically, the fill material within the encapsulating membrane after injection may be a liquid, a semi-solid such as a gel, or a solid such as a cross-linked polymer. The fill material may or may not be sealed within the encapsulating membrane. | 02-16-2012 |
| 20120028904 | METHODS, SYSTEMS, AND COMPOSITIONS FOR CALPAIN INHABITION - Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains. | 02-02-2012 |
| 20120021992 | METHODS FOR IMPROVING NEUROLOGICAL OUTCOME AFTER NEURAL INJURY AND NEURODEGENERATIVE DISEASE - Thymosin β | 01-26-2012 |
| 20110307426 | Personalized Health Risk Assessment For Critical Care - A method for providing a personalized health risk of a patient includes receiving training data corresponding to a plurality of patients and target data corresponding to a target patient; generating model data based on the training data according to an anomaly detection method; either determining whether the target data is anomalous with respect to the training data, or determining the extent to which the target data is anomalous with respect to the training data; and either indicating whether the target patient is at risk of the adverse outcome, or indicating the extent to which the target patient is at risk of the adverse outcome. | 12-15-2011 |
| 20110158969 | COMPOSITIONS AND METHODS FOR USING STROMAL CELLS TO ENHANCE TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES - The present invention provides novel methods and compositions for the treatment of injuries to the mammalian central nervous system. These methods involve administering stromal cells in combination with a blood-brain barrier permeabilizing agent in order to enhance neurorestoration, functional neurological recovery, stromal cell engraftment, and treatment of neurodegenerative diseases. | 06-30-2011 |
| 20110087190 | Cardiac Repair, Resizing and Reshaping Using the Venous System of the Heart - Structurally supportive material is implanted or injected into cardiac veins as discrete masses at various sites in the cardiac venous system to reinforce the myocardium for the purpose of preventing, moderating, stopping or reversing negative cardiac remodeling due to various adverse cardiac conditions, both acute and chronic, or for the purpose of treating localize anomalies of the heart, or for both purposes. The sites may be arranged in a pattern about one or more chambers of the heart such that the masses cooperatively reduce stress in the chamber wall and reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Patterns of distribution of discrete masses in the heart for global resizing and reshaping may also be used as is or augmented by supplemental patterns to treat localized conditions such as myocardial infarctions and overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy. | 04-14-2011 |
| 20090287155 | FIXATION APPARATUS FOR A MEDICAL DEVICE - A fixation apparatus for attaching a medical device to a patient includes an attachment feature attached to the medical device and configured to cooperate with one or more surgical staples to facilitate stapling of the medical device to the patient. The attachment feature includes a staple receiving portion including two ends, each of which has a staple retaining end disposed adjacent thereto. The staple receiving portion is configured to receive surgical staples, and the staple retaining ends are configured to inhibit the staple receiving portion from dislodging from the surgical staples. | 11-19-2009 |
| 20090221948 | SYSTEM AND METHOD FOR DELIVERY OF REGIONAL CITRATE ANTICOAGULATION TO EXTRACORPOREAL BLOOD CIRCUITS - The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable soultes. | 09-03-2009 |
| 20090169527 | MATERIALS FROM BONE MARROW STROMAL CELLS FOR USE IN FORMING BLOOD VESSELS AND PRODUCING ANGIOGENIC AND TROPHIC FACTORS - A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair. | 07-02-2009 |
| 20090017559 | Methods for diagnosing renal disorders - The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension. | 01-15-2009 |
